Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.